$1.41
-0.01 (-0.70%)
Open$1.41
Previous Close$1.42
Day High$1.44
Day Low$1.39
52W High$1.88
52W Low$0.81
Volume—
Avg Volume489.8K
Market Cap68.80M
P/E Ratio—
EPS$-1.48
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+393.6% upside
Current
$1.41
$1.41
Target
$6.96
$6.96
$5.52
$6.96 avg
$10.50
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.44M | 13.53M | 15.01M |
| Net Income | -947,825 | -765,390 | -987,033 |
| Profit Margin | -6.6% | -5.7% | -6.6% |
| EBITDA | -1,267,375 | -1,123,871 | -1,333,015 |
| Free Cash Flow | -656,212 | -624,188 | -715,122 |
| Rev Growth | +21.5% | +1.8% | +6.7% |
| Debt/Equity | 0.93 | 0.92 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |